Inhibitor of mitogen-activated protein kinase kinase (MKK / MEK). Acts by binding to the inactivated form of MEK, thereby preventing its phosphorylation by cRAF or MEK kinase (IC50
= 2-7 μ
M). Inhibits cell growth and proliferation in acute myelogenous leukemia (AML) cell lines; causes G1
arrest by blocking p53-dependent p21 induction. Enhances embryonic stem cell self-renewal. Also available as part of the MAPK Cascade Inhibitor Tocriset™
and MAPK Inhibitor Tocriset™
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells.
Kojima K, Konopleva M, Samudio IJ et al.
PD 98059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.
Alessi et al.
A synthetic inhibitor of the mitogen-activated protein kinase cascade.
Dudley et al.
Effects of mitogen-activated protein kinase kinase inhibitor PD 98059 on antigen challenge of guinea-pig airways in vitro.
Tsang et al.
BMP4 supports self-renewal of embryonic stem cells by inhibiting mitogen-activated protein kinase pathways.
Qi et al.
The citations listed below are publications that use Tocris products. Selected citations for PD 98059 include:
Showing Results 1 - 10 of 56